Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANCE Trial
2023-504504-28-00Phase 3Authorised
- Sponsor
- Hamilton Health Sciences
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3 trial of warfarin, rivaroxaban, phenprocoumon, edoxaban, apixaban and 1 more in Atrial fibrillation (AFib) (2 arms), sponsored by Hamilton Health Sciences. Primary endpoint: Major bleeding at 30 days. Planned start Oct 2024; status: authorised.
02
Drugs
warfarinrivaroxabanphenprocoumonedoxabanapixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2023-504504-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504504-28-00.